Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 3NET 2Genitourinary 2Gastrointestinal 2Breast 2Head & Neck 1

Conditions

Prostatic Neoplasms 2Diarrhea 1

Interventions

Docetaxel 69pembrolizumab 48Prednisone 43Nivolumab 40enzalutamide 38Gemcitabine 37Sunitinib 36Cyclophosphamide 29Radiotherapy 26Magnetic Resonance Spectroscopy 26Leuprolide 25Abiraterone Acetate 25Sorafenib 23Everolimus 23Cisplatin 23bicalutamide 19atezolizumab 18Carboplatin 18Bevacizumab 18avelumab 17Radiosurgery 17Goserelin 17Interleukin-2 16abiraterone 15fludarabine 14Doxorubicin 14olaparib 13durvalumab 13cabozantinib 13acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Octreotide × Genitourinary × Clear all
NCT01469338 2014-11-24

Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel

University of Southern California

Phase 2 Terminated
9 enrolled
Genitourinary

Diarrhea, Prostatic Neoplasms

NCT00510224 2013-12-11

Sandostatin for Patients With Androgen Independent Prostate Cancer

University of California, San Francisco

Phase 2 Terminated
13 enrolled 4 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡